Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is the developer of blockbuster drugs Ozempic, Rybelsus, and Wegovy. The popularity of these treatments is fueling impressive growth and a bright outlook.

Novo Nordisk's Magic Run Continues Even With Increasing Competition

ASML Hld

AstraZeneca

GlaxoSmithKline

L'Oreal SA

Novartis

Roche Holding AG

SAP SE

Sanofi

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk , plans to invest up to $7 billion annually by 2030, the Financial Times reported on Monday.

Novo Nordisk's controlling shareholder plans to invest up to $7 bln a year by 2030 - FT

Novo Nordisk is selling Wegovy faster than it can be made. It's scaling up production as well as acquiring more capacity.

Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?

Sales from Ozempic, Rybelsus, and Wegovy are increasing at unprecedented rates. Investors have continued to buy up stock in Novo Nordisk as its magic run continues.

Don't Worry About Novo Nordisk's Premium Stock Price. It's Still a Buy.

Novo Nordisk just acquired Catalent, a subcontractor for the company's drug production. Per the deal, Novo Nordisk will take over three of Catalent's production plants.

Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited

Eli Lilly

Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.

Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

Vertex Pharmaceuticals

Eli Lilly has major catalysts ahead. Novo Nordisk delivered strong growth in 2023 and could top that performance in 2024.

3 Stocks That Could Trounce the Market in 2024

Catalent

Catalent reported second-quarter revenue slightly above Wall Street estimates on Friday, days after the contract drug manufacturer agreed to a $16.5-billion acquisition offer from Novo Nordisk's parent firm.

Catalent Q2 sales inch past estimates amid takeover by Novo Holdings

Merck

Demand is surging for weight-loss treatments that are being rolled out by major pharmaceutical companies. Investors are still trying to assess the full market opportunity and competitive landscape.

Here's Why Merck, Eli Lilly, and Novo Nordisk Stocks Rose 11% Last Month

DexCom

Novo Nordisk leads a market that is predicted to grow by leaps and bounds. DexCom's work in diabetes care is much needed -- and just getting started.

Prediction: 2 Stocks That Could Trounce the Market

Novo Nordisk's obesity sales more than doubled last quarter. Ozempic and Wegovy account for a significant part of total revenue.

How Important Are Ozempic and Wegovy to Novo Nordisk's Business?

U.S. drug regulators in November found quality control lapses at the Bloomington, Indiana factory of contract drug manufacturer Catalent , including discovery of a "pest" on the manufacturing line, according to an inspection report.

US FDA finds control lapses at Catalent plant being sold to Novo

The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception.

Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks

Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.

Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes

Novo Nordisk (NYSE:NVO)'s takeover of three production sites through the acquisition of Catalent Inc (NYSE:CTLT) is a sensible move, analysts say, and will help meet demand for its flagship weight loss drugs. Though Catalent already provides two filling lines for Novo's injectable Wegovy drug in Belgium and the US, transfer of ownership will see production capacity increase further, according to JP Morgan analysts, eventually also including the Ozempic treatment.

Novo Nordisk acquisition of Catalent production sensible, analysts say

Novo Holdings, the holding company of Novo Nordisk , said on Tuesday it was investing in Indian private hospital chain Manipal Hospitals, its largest investment in Asia to date.

Novo Holdings invests in hospital chain Manipal in India

Its controlling shareholder has agreed to acquire U.S. contract manufacturer Catalent. The all-cash transaction's enterprise value is $16.5 billion.

Why Novo Nordisk Stock Crushed the Market on Monday

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

Big drug companies have substantial free cash flow from older, cash-cow drugs, manageable debt burdens, and investor pressure to find new growth opportunities.

Novo Nordisk Makes the Latest Big Pharma Deal. Why More Are Coming.

The shares of pharmaceutical concern Catalent Inc (NYSE:CTLT) are surging today, after news that Novo Holdings, the controlling shareholder of Novo Nordisk (NVO), is purchasing the company for $11.5 billion.

Novo Holdings Buyout Sends Catalent Stock Surging

Shares of syringe maker Catalent (CTLT) soared 10% in early trading after it signed a deal to be sold to the controlling shareholder of Novo Nordisk (NVO) for $16.5 billion.

Novo Nordisk Parent Buys Catalent in $16.5 Billion Cash Deal

Catalent (NYSE: CTLT ) stock is climbing higher on Monday after the company agreed to sell itself to Novo Nordisk (NYSE: NVO ) parent Novo Holdings for $16.5 billion. The transaction will have Novo Holdings paying $63.50 per share in cash for CTLT stock.

Catalent (CTLT) Stock Pops 10% on Sale to Novo Nordisk

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

News for Novo Nordisk Stock (NVO)